Sales fell 4.3 percent to 14.1 billion euros, hit by a weak U.S. dollar and Japanese yen, the world's largest unlisted drugmaker said on Tuesday.

Excluding currency effects, sales rose 1.4 percent.

The company said it expects sales for 2014 to be flat and operating income to be slightly higher than last year, saying the market for innovative drugs will not be easy in the coming years and highlighting the effects of patents that are expiring.

(Reporting by Frank Siebelt and Marilyn Gerlach; Editing by Victoria Bryan)